Background: Contemporary treatment for COVID-19 includes the use of SARS-2-CoV direct-acting antivirals (DAAs). An FDA assessment in the Medicare and Veterans Affairs population has suggested that individual agents in this class have significant differences in drug-drug interaction (DDI) potential based on their pharmacokinetic profiles; however, the clinical impact is not well established. We sought to [...]

Background: More frequently, clinicians encounter patients with mild-to-moderate COVID-19 (defined as patients whose oxygen saturation remains above 94% on room air)1 in the hospital setting.2 These patients may have acquired COVID-19 in the hospital or have tested positive for COVID-19 while presenting to the hospital for another condition.3 Many of these patients are high risk [...]

Case Presentation: We present the case of a 41-year-old male with a history of latent syphilis and recently diagnosed (about 10 days before admission) human immunodeficiency virus (HIV) and Mpox who presented to the ER with malaise, lethargy, and worsening cutaneous lesions. Clinical exam was notable for widespread skin lesions and purulent drainage from a [...]

Background: Hepatitis C virus (HCV) is a leading cause for liver cirrhosis and one of the commonest indications for liver transplantation. The introduction of direct acting antiviral (DAA) medications have revolutionized the treatment for HCV. Prior to 2014, the treatment for HCV consisted of interferon and ribavirin which yielded a sustained virologic response (SVR) of [...]